文献速递脊柱关节炎

非放射学轴性脊柱关节炎患者接受开放标签阿达木单抗治疗缓解的预测因素:ABILITY-3研究

Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study.
PubMed 文献 · RMD Open · 2019-06-07

ABILITY-3研究纳入673例活动性非放射学轴性脊柱关节炎(nr-axSpA)患者,接受阿达木单抗40mg隔周治疗28周开放标签导入期。分析基线预测因素发现,第12周时年轻年龄(≤45岁)、男性、HLA-B27阳性及较高SPARCC MRI骶髂关节评分是ASDAS ID和ASAS PR缓解的一致预测因素,最终访视分析结果相似。

要点

  • 年轻(≤45岁)、男性、HLA-B27阳性及较高SPARCC MRI骶髂关节评分预测第12周缓解。
  • 上述预测因素在最终访视(至第28周)分析中结果基本一致。
  • 其他变量未 consistently 预测缓解。

核心结论

  • 在活动性nr-axSpA接受阿达木单抗治疗的患者中,年轻年龄、男性、HLA-B27阳性及较高SPARCC MRI骶髂关节评分是一致且强烈的基线缓解预测因素。

研究设计与样本

  • ABILITY-3研究纳入673例成人nr-axSpA患者,接受阿达木单抗40mg隔周治疗28周开放标签导入期;采用逐步逻辑回归识别第12周及最终访视缓解的基线预测因素,仅纳入无缺失数据的患者。

主要发现

  • 第12周ASDAS ID分析纳入593例,ASAS PR分析纳入596例。
  • 年轻年龄(≤45岁)、男性、HLA-B27阳性及较高SPARCC MRI骶髂关节评分在ASDAS ID和ASAS PR中均一致预测第12周缓解。
  • 最终访视分析结果与第12周分析基本相似。
  • 其他变量未一致预测缓解。

关键数值与推荐

  • 临床缓解定义为ASDAS inactive disease(ASDAS ID;评分<1.3)。
  • 临床缓解定义为ASAS部分缓解(ASAS PR;四个ASAS域中每个评分<2/10)。

临床怎么用

  • 对于活动性nr-axSpA患者,基线年轻(≤45岁)、男性、HLA-B27阳性及较高SPARCC MRI骶髂关节评分可提示阿达木单抗治疗后更可能达到缓解。

局限性

  • 原文未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This analysis assessed baseline predictors of remission in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who received open-label adalimumab therapy. METHODS: ABILITY-3 enrolled 673 adult patients with nr-axSpA who had objective evidence of inflammation by MRI or elevated high-sensitivity C reactive protein at screening, active disease and an inadequate response to two or more non-steroidal anti-inflammatory drugs. Patients received adalimumab 40 mg every other week during a 28-week open-label lead-in period. Clinical remission was defined as Ankylosing Spondylitis Disease Activity Score inactive disease (ASDAS ID; score <1.3) and Assessment of SpondyloArthritis international Society partial remission (ASAS PR; score <2/10 in each of the four ASAS domains). Stepwise logistic regression was used to identify baseline predictors of remission at week 12 and at final visit (last postbaseline visit up to week 28). Only patients without missing data were included. RESULTS: Overall, 593 patients were included in the ASDAS ID and 596 in the ASAS PR analysis at week 12. Younger age (≤45 years), male sex, positive human leucocyte antigen (HLA)-B27 and higher Spondyloarthritis Research Consortium of Canada (SPARCC) MRI sacroiliac joint score were consistent predictors of remission by both ASAS ID and ASDAS PR at week 12. Results were generally similar in the final visit analysis. Other variables did not consistently predict remission. CONCLUSIONS: In ABILITY-3, consistent and strong baseline predictors of remission included younger age, male sex, HLA-B27 positivity and higher SPARCC MRI sacroiliac joint score among patients with active nr-axSpA receiving adalimumab therapy, similar to previous findings in ankylosing spondylitis.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Sieper J, Landewé R, Magrey M, et al. Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study. RMD Open. 2019. PMID: 31245052. doi:10.1136/rmdopen-2019-000917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。